Hilary J. Vernon

Hilary J. Vernon

Auto-generated profile, based on publicly available information

Hilary J. Vernon

Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
SSSiddharth Srivastava
Siddharth Srivastava
JCJulie S. Cohen
Julie S. Cohen
HVHilary Vernon
Hilary Vernon
KBKristin Barañano
Kristin Barañano
RMRebecca McClellan
Rebecca McClellan
AFAli Fatemi
Ali Fatemi

20 December 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JBJoel S. Benjamin
Joel S. Benjamin
GPGenay O. Pilarowski
Genay O. Pilarowski
GCGiovanni A. Carosso
Giovanni A. Carosso
LZLi Zhang
Li Zhang
DHDavid. L. Huso
David. L. Huso
HBHans Tomas Bjornsson
Hans Tomas Bjornsson
Kabuki syndrome is a Mendelian intellectual disability syndrome caused by mutations in either of two genes (KMT2D and KDM6A) involved in chromatin accessibility. We previously showed that an agent that promotes chromatin opening, the histone deacetylase inhibitor (HDACi) AR-42, ameliorates the deficiency of adult neurogenesis in the granule cell layer of the dentate gyrus and rescues hippocampal memory defects in a mouse model of Kabuki syndrome (Kmt2d+/βGeo). Unlike a drug, a dietary intervention could be quickly transitioned to the clinic. Therefore, we have explored whether treatment with a ketogenic diet could lead to a similar rescue through increased amounts of beta-hydroxybutyrate, an endogenous HDACi. Here, we report that a ketogenic diet in Kmt2d+/βGeo mice modulates H3ac and H3K4me3 in the granule cell layer, with concomitant rescue of both the neurogenesis defect and hippocampal memory abnormalities seen in Kmt2d+/βGeo mice; similar effects on neurogenesis were observed on exogenous administration of beta-hydroxybutyrate. These data suggest that dietary modulation of epigenetic modifications through elevation of beta-hydroxybutyrate may provide a feasible strategy to treat the intellectual disability seen in Kabuki syndrome and related disorders.

1 March 2021 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
WTW. Reid Thompson
W. Reid Thompson
BHBrittany Hornby
Brittany Hornby
RMRyan Manuel
Ryan Manuel
EBElena Bradley
Elena Bradley
JLJanice Laux
Janice Laux
HVHilary J. Vernon
Hilary J. Vernon
Purpose To evaluate effectiveness of elamipretide in Barth syndrome (BTHS), a genetic condition of defects in TAZ, which causes abnormal cardiolipin on the inner mitochondrial membrane. Methods We performed a randomized, double-blind, placebo-controlled crossover trial followed by an open-label extension in BTHS to test the effect of elamipretide, a mitochondrial tetrapeptide that interacts with cardiolipin. In part 1, 12 subjects were randomized to 40 mg per day of elamipretide or placebo for 12 weeks, followed by a 4-week washout and then 12 weeks on the opposite arm. Ten subjects continued on the open-label extension (part 2) of 40 mg per day of elamipretide, with eight subjects reaching 36 weeks. Primary endpoints were improvement on the 6-minute walk test (6MWT) and improvement on a BTHS Symptom Assessment (BTHS-SA) scale. Results In part 1 neither primary endpoint was met. At 36 weeks in part 2, there were significant improvements in 6MWT (+95.9 m, p = 0.024) and BTHS-SA (-2.1 points, p = 0.031). There were also significant improvements in secondary endpoints including knee extensor strength, patient global impression of symptoms, and some cardiac parameters. Conclusion In this interventional clinical trial in BTHS, daily administration of elamipretide led to improvement in BTHS symptoms.

1 August 2015 in JAMA Pediatrics
Verified
Journal Article
Closed access
PDF file
HVHilary J. Vernon
Hilary J. Vernon
Review from JAMA Pediatrics — Inborn Errors of Metabolism — Advances in Diagnosis and Therapy

13 February 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
YZYuri A. Zarate
Yuri A. Zarate
CHConstance Hicks-Smith
Constance Hicks-Smith
CGCarol Greene
Carol Greene
MAMary‐Alice Abbott
Mary‐Alice Abbott
VSVictoria M. Siu
Victoria M. Siu
WCWendy K. Chung
Wendy K. Chung

6 August 2021 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
CTCarolyn Taylor
Carolyn Taylor
EREmily S. Rao
Emily S. Rao
GPGermaine Pierre
Germaine Pierre
ECEstathia Chronopoulou
Estathia Chronopoulou
BHBrittany Hornby
Brittany Hornby
HVHilary J. Vernon
Hilary J. Vernon